Senti Biosciences (NASDAQ:SNTI – Get Free Report) and ZIVO Bioscience (NASDAQ:ZIVO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
This table compares Senti Biosciences and ZIVO Bioscience’s net margins, return on equity and return on assets.
|Return on Equity
|Return on Assets
This is a breakdown of recent ratings and price targets for Senti Biosciences and ZIVO Bioscience, as reported by MarketBeat.com.
|Strong Buy Ratings
Institutional & Insider Ownership
27.4% of Senti Biosciences shares are held by institutional investors. Comparatively, 14.1% of ZIVO Bioscience shares are held by institutional investors. 12.5% of Senti Biosciences shares are held by company insiders. Comparatively, 13.4% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Senti Biosciences has a beta of 3.08, indicating that its stock price is 208% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Valuation & Earnings
This table compares Senti Biosciences and ZIVO Bioscience’s top-line revenue, earnings per share (EPS) and valuation.
|Earnings Per Share
ZIVO Bioscience has lower revenue, but higher earnings than Senti Biosciences.
Senti Biosciences beats ZIVO Bioscience on 6 of the 10 factors compared between the two stocks.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About ZIVO Bioscience
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.